Tokyo endoscope AI developer raises $43M for image analysis software

In Silico
AI Medical Service plans to use its latest proceeds to bring on more staff and equipment as it eyes regulatory submissions as well as to fuel its expansion overseas. (Pixabay/Geralt)

AI Medical Service, a Tokyo-based developer of artificial intelligence programs that analyze endoscopy images for potential diagnosis in real time, has raised about $43 million to help support its clinical trials and the commercialization of its products.

The series B round included funds from Globis Capital Partners, World Innovation Lab and the Sony Innovation Fund by Innovation Growth Ventures as well as additional backers. The company previously raised more than $9 million in August 2018 from the Incubate Fund.

“Our company was founded on the desire to solve issues with endoscopies in the clinics,” CEO Tomohiro Tada said in a statement. “In January 2018, we published the world's first article on AI in gastric cancer in cooperation with the Joint Research Group and have since published a number of scientific articles on topics including AI in esophageal cancer, colorectal cancer, and capsule endoscopy AI.”


CIOs’ Perspectives: Driving Clinical Trial Innovation with a Unified Platform

IT is being challenged with either trying to fix and maintain an already complex system of solution integrations, or exploring driving business impact by unifying its systems under one platform. Attend and learn about the IT benefits to shifting resources away from disparate systems and moving towards a unified platform.

AI Medical Service also plans to use the latest proceeds to bring on more staff and equipment as it eyes regulatory submissions as well as to fuel its overseas expansion.

“Endoscopic treatment is a medical field that needs to be promoted in society because it leads to the improvement of diagnostic accuracy of diseases,” said World Innovation Lab general partner Masataka Matsumoto. “However, the industry is facing key hurdles including long hours required for analysis and a shortage of human resources.”

AI Medical Service has also partnered with medical institutions in Japan to build a large database of endoscopic images and data, Matsumoto said.

Suggested Articles

Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.

The FDA approved its first rapid in vitro diagnostic for confirming Ebola virus infections with potential results in about a half-hour.

Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.